Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.

@article{Hudry2006CostutilityMO,
  title={Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.},
  author={Joumana Hudry and Juha O. Rinne and T Ker{\"a}nen and Laurent Eckert and John Cochran},
  journal={The Annals of pharmacotherapy},
  year={2006},
  volume={40 4},
  pages={651-7}
}
BACKGROUND The economic burden of Parkinson's disease (PD) is high, especially in patients experiencing motor fluctuations. Rasagiline has demonstrated efficacy against symptoms of PD in early and advanced stages of the disease. OBJECTIVE To assess the cost-utility of rasagiline and entacapone as adjunctive therapies to levodopa versus standard levodopa care in PD patients with motor fluctuations in Finland. METHODS A 2 year probabilistic Markov model with 3 health states: "25% or less off… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.

Cost - utility model of rasagiline in the treatment of advanced Parkinson ' s disease in Finland

  • M. CochranJ
  • Annals of Pharmacotherapy
  • 2006

Similar Papers

Loading similar papers…